Stock listing
NASDAQ:ENVB Enveric Biosciences, Inc. Stock
Home listing (NASDAQ) of Enveric Biosciences, Inc.
Follow Enveric Biosciences, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ENVB
$1.35 USD -0.07 (-4.9%)
Close on Nov 20, 2026
- Day range
- $1.33 – $1.49 USDNov 20, 2026
- Volume
- 62,193 sharesNov 20, 2026
- Market cap
- $6.04M USDAt the close on Nov 20, 2026 · price × 4.48M shares outstanding
- 52-week range
- $1.17 – $13.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $84,989 USDMedian day 42,959 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ENVB · Home | $1.35 USD | -0.07 (-4.9%) | 62,193 | $1.38 | $1.49 | $1.33 | $1.42 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ENVB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.35 | -0.07 | -4.9% | $1.38 | $1.49 | $1.33 | 62,193 | |
| $1.42 | +0.01 | +0.7% | $1.479 | $1.479 | $1.36 | 37,009 | |
| $1.41 | -0.03 | -2.1% | $1.43 | $1.475 | $1.41 | 14,147 | |
| $1.44 | -0.075 | -5.0% | $1.51 | $1.54 | $1.44 | 34,608 | |
| $1.515 | -0.005 | -0.3% | $1.52 | $1.55 | $1.51 | 17,243 | |
| $1.52 | +0.03 | +2.0% | $1.53 | $1.54 | $1.47 | 32,237 | |
| $1.49 | -0.02 | -1.3% | $1.381 | $1.579 | $1.381 | 9,975 | |
| $1.51 | +0.07 | +4.9% | $1.47 | $1.53 | $1.455 | 38,140 | |
| $1.44 | +0.016 | +1.1% | $1.41 | $1.47 | $1.41 | 18,994 | |
| $1.424 | +0.024 | +1.7% | $1.39 | $1.46 | $1.38 | 10,393 | |
| $1.40 | -0.06 | -4.1% | $1.46 | $1.46 | $1.37 | 39,383 | |
| $1.46 | -0.04 | -2.7% | $1.58 | $1.58 | $1.43 | 35,559 | |
| $1.50 | +0.05 | +3.4% | $1.45 | $1.51 | $1.41 | 43,101 | |
| $1.45 | +0.02 | +1.4% | $1.41 | $1.54 | $1.41 | 28,845 | |
| $1.43 | -0.03 | -2.1% | $1.47 | $1.481 | $1.40 | 11,982 | |
| $1.46 | -0.01 | -0.7% | $1.43 | $1.49 | $1.42 | 27,933 | |
| $1.47 | +0.05 | +3.5% | $1.485 | $1.489 | $1.38 | 19,166 | |
| $1.42 | +0.04 | +2.9% | $1.356 | $1.44 | $1.356 | 56,485 | |
| $1.38 | -0.02 | -1.4% | $1.40 | $1.41 | $1.30 | 29,335 | |
| $1.40 | -0.06 | -4.1% | $1.44 | $1.505 | $1.39 | 33,300 | |
| $1.46 | -0.05 | -3.3% | $1.51 | $1.57 | $1.44 | 35,100 | |
| $1.51 | +0.07 | +4.9% | $1.465 | $1.588 | $1.43 | 84,500 | |
| $1.44 | +0.05 | +3.6% | $1.375 | $1.445 | $1.375 | 31,300 | |
| $1.39 | +0.01 | +0.7% | $1.38 | $1.425 | $1.36 | 31,500 | |
| $1.38 | -0.01 | -0.7% | $1.35 | $1.442 | $1.35 | 22,500 | |
| $1.39 | +0.02 | +1.5% | $1.37 | $1.438 | $1.35 | 21,200 | |
| $1.37 | -0.03 | -2.1% | $1.38 | $1.45 | $1.33 | 162,800 | |
| $1.40 | -0.07 | -4.8% | $1.43 | $1.49 | $1.38 | 102,100 | |
| $1.47 | +0.02 | +1.4% | $1.43 | $1.52 | $1.40 | 114,600 | |
| $1.45 | -0.07 | -4.6% | $1.48 | $1.495 | $1.44 | 50,200 | |
| $1.52 | +0.025 | +1.7% | $1.47 | $1.531 | $1.46 | 64,900 | |
| $1.495 | +0.025 | +1.7% | $1.45 | $1.51 | $1.45 | 41,400 | |
| $1.47 | -0.04 | -2.6% | $1.53 | $1.53 | $1.43 | 51,000 | |
| $1.51 | +0.03 | +2.0% | $1.46 | $1.53 | $1.45 | 54,300 | |
| $1.48 | +0.02 | +1.4% | $1.51 | $1.53 | $1.46 | 72,900 | |
| $1.46 | -0.025 | -1.7% | $1.455 | $1.48 | $1.41 | 83,600 | |
| $1.485 | +0.035 | +2.4% | $1.44 | $1.53 | $1.421 | 57,100 | |
| $1.45 | -0.02 | -1.4% | $1.46 | $1.48 | $1.423 | 45,800 | |
| $1.47 | -0.03 | -2.0% | $1.51 | $1.56 | $1.45 | 54,600 | |
| $1.50 | -0.045 | -2.9% | $1.522 | $1.53 | $1.48 | 38,200 | |
| $1.545 | -0.02 | -1.3% | $1.57 | $1.58 | $1.478 | 84,700 | |
| $1.565 | +0.025 | +1.6% | $1.576 | $1.60 | $1.52 | 113,400 | |
| $1.54 | -0.02 | -1.3% | $1.54 | $1.608 | $1.52 | 46,300 | |
| $1.56 | -0.06 | -3.7% | $1.64 | $1.649 | $1.55 | 51,300 | |
| $1.62 | +0.03 | +1.9% | $1.62 | $1.649 | $1.519 | 158,300 | |
| $1.59 | +0.10 | +6.7% | $1.493 | $1.64 | $1.489 | 169,600 | |
| $1.49 | +0.03 | +2.1% | $1.45 | $1.54 | $1.45 | 51,600 | |
| $1.46 | -0.02 | -1.4% | $1.47 | $1.53 | $1.44 | 75,300 | |
| $1.48 | +0.06 | +4.2% | $1.423 | $1.538 | $1.41 | 104,200 | |
| $1.42 | -0.04 | -2.7% | $1.45 | $1.48 | $1.42 | 38,700 | |
| $1.46 | +0.005 | +0.3% | $1.45 | $1.46 | $1.42 | 11,500 | |
| $1.455 | +0.035 | +2.5% | $1.48 | $1.48 | $1.40 | 29,800 | |
| $1.42 | +0.03 | +2.2% | $1.38 | $1.452 | $1.38 | 51,500 | |
| $1.39 | -0.05 | -3.5% | $1.40 | $1.45 | $1.36 | 56,742 | |
| $1.44 | 0.00 | 0.0% | $1.47 | $1.47 | $1.374 | 42,959 | |
| $1.44 | +0.07 | +5.1% | $1.40 | $1.44 | $1.37 | 21,276 | |
| $1.37 | 0.00 | 0.0% | $1.39 | $1.39 | $1.35 | 20,993 | |
| $1.37 | 0.00 | 0.0% | $1.35 | $1.38 | $1.33 | 38,529 | |
| $1.37 | 0.00 | 0.0% | $1.41 | $1.41 | $1.34 | 22,213 | |
| $1.37 | 0.00 | 0.0% | $1.371 | $1.39 | $1.34 | 36,701 | |
| $1.37 | -0.09 | -6.2% | $1.47 | $1.52 | $1.17 | 403,135 | |
| $1.46 | +0.05 | +3.5% | $1.44 | $1.49 | $1.399 | 64,794 | |
| $1.41 | -0.02 | -1.4% | $1.44 | $1.471 | $1.37 | 58,200 | |
| $1.43 | +0.04 | +2.9% | $1.40 | $1.44 | $1.38 | 89,150 | |
| $1.39 | +0.08 | +6.1% | $1.34 | $1.39 | $1.29 | 132,766 |
Splits
7 splits since 2008 · NASDAQ:ENVB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation | |
| 1-for-15 | Consolidation | |
| 1-for-50 | Consolidation | |
| 1-for-4 | Consolidation | |
| 1-for-25 | Consolidation | |
| 1-for-17.61 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:ENVB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
Latest deck · Jun 9, 2026
Investor Presentation (June 2026)
Investor deck · 15 slides
Latest news
Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
Nov 13, 2026
Closed $1.44 (-5.0%) on Nov 16, 2026
Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study
Nov 4, 2026
Closed $1.46 (-2.7%) on Nov 4, 2026
Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies
Oct 21, 2026
Closed $1.51 (+4.9%) on Oct 21, 2026
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Sep 15, 2026
Closed $1.46 (-1.4%) on Sep 15, 2026
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
Sep 1, 2026
Closed $1.37 (0.0%) on Sep 1, 2026
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
Aug 14, 2026
Closed $1.48 (-3.6%) on Aug 17, 2026
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
Aug 5, 2026
Closed $1.67 (-1.2%) on Aug 5, 2026
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
Jul 28, 2026
Closed $1.33 (-0.7%) on Jul 28, 2026
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Jun 29, 2026
Closed $1.38 (-2.8%) on Jun 29, 2026
Enveric Biosciences Announces Participation in 2026 BIO International Convention
Jun 16, 2026
Closed $1.37 (-7.4%) on Jun 16, 2026
Enveric Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 33 in the last 12 months · 149 in all · newest Nov 13, 2026 · oldest 2021
- Decks
- 19 decks · latest Jun 9, 2026
Where Enveric Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ENVB · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ENVB | BOATS | United States | USD |
| gettex:SLZ0 | gettex | Germany | EUR |
| Frankfurt:SLZ0 | Frankfurt | Germany | EUR |
| Munich:SLZ0 | Munich | Germany | EUR |
| Stuttgart:SLZ | Stuttgart | Germany | EUR |
Valuation
Price/book 1.1× against a median of 2.1×: 4th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $429,455 USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.76
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Enveric Biosciences, Inc. · NASDAQ:ENVB | US$6.04M | US$429,455 | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 0.76 |
| FibroBiologics, Inc. · NASDAQ:FBLG | US$6.34M | US$5.17M | n/a | n/a | n/a | 3.5× | n/a | 0.0× | 0.34 |
| GT Biopharma, Inc. · NASDAQ:GTBP | US$6.33M | −US$3.60M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | 1.57 |
| Kyntra Bio, Inc. · NASDAQ:KYNB | US$6.32M | −US$33.97M | n/a | −6.4× | n/a | n/a | −326.0% | n/a | 1.58 |
| Acurx Pharmaceuticals, Inc. · NASDAQ:ACXP | US$6.30M | −US$3.35M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| TrivarX Limited · ASX:TRI | US$6.11M | US$4.58M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | n/a |
| Medicofarma Biotech Spolka Akcyjna · NEWCONNECT:MDB | US$6.03M | US$6.03M | n/a | 314× | n/a | 5.4× | n/a | 0.0× | n/a |
| Addex Therapeutics Ltd · SIX:ADXN | US$5.96M | US$5.13M | n/a | 68.2× | n/a | 2.6× | n/a | 0.0× | n/a |
| Argenica Therapeutics Ltd · ASX:AGN | US$5.95M | US$1.74M | n/a | n/a | n/a | 1.5× | n/a | 0.0× | n/a |
| Marvel Biosciences Corp · TSXV:MRVL | US$5.91M | US$6.04M | n/a | n/a | n/a | n/a | n/a | n/a | 0.91 |
| Exicure, Inc. · NASDAQ:XCUR | US$5.89M | US$4.67M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | 0.49 |
| Median of the others | US$6.07M | US$4.62M | 68.2× | 2.1× | −326.0% | 0.0× | 1.11 |
Team and board
Officers
| Officer | Role |
|---|---|
| Joseph Tucker | Chief Executive Officer, Director |
| Kevin Coveney | Chief Financial Officer |
| Jillian Hagel | Vice President, Innovation |
Board
| Director | Role |
|---|---|
| Michael D. Webb | Board Chair |
| Frank Pasqualone | Director, Chair of Compensation and Nominating Committees |
| George Kegler | Director, Chair of the Audit Committee |
| Joseph Tucker | Chief Executive Officer, Director |
| Marcus Schabacker | Director, Chair of Science and Technology Committee |
| Sheila DeWitt | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 | −5.3% |
| Q2 2026 | Aug 14, 2026 | −2.0% |
| Q1 2026 | May 19, 2026 | +2.3% |
| Q4 2025 | Mar 27, 2026 | −3.8% |
| Q3 2025 | Nov 14, 2025 | −9.0% |
| Q2 2025 | Aug 14, 2025 | −0.9% |
| Q1 2025 | May 13, 2025 · Before open | +5.2% |
| Q4 2024 | Mar 28, 2025 · After close | −5.4% |
| Q3 2024 | Nov 14, 2024 · After close | −8.1% |
| Q2 2024 | Aug 12, 2024 · After close | +1.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · After close | +14.2% |
| Q4 2023 | Mar 26, 2024 · Before open | +0.9% |
| Q3 2023 | Nov 13, 2023 · After close | −1.3% |
| Q2 2023 | Aug 11, 2023 · After close | −1.5% |
| Q1 2023 | May 15, 2023 · Before open | +3.5% |
| Q4 2022 | Mar 31, 2023 · After close | −4.0% |
| Q3 2022 | Nov 14, 2022 · After close | −0.6% |
| Q2 2022 | Aug 12, 2022 · After close | −1.4% |
| Q1 2022 | May 13, 2022 · After close | +2.5% |
| Q4 2021 | Mar 31, 2022 · After close | −5.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (June 2026) | Investor deck | 15 slides | Jun 9, 2026 |
| Investor Presentation (January 2026) | Investor deck | 17 slides | January 2026 |
| Investor Presentation (August 2025) | Investor deck | 14 slides | Aug 29, 2025 |
| Investor Presentation (August 2025) | Investor deck | 15 slides | August 2025 |
| Investor Presentation (February 2025) | Investor deck | 15 slides | February 2025 |
| Investor Presentation (January 2025) | Investor deck | 15 slides | January 2025 |
| Investor Presentation (August 2024) | Investor deck | 15 slides | Aug 21, 2024 |
| Investor Presentation (January 2024) | Investor deck | 21 slides | January 2024 |
| Investor Presentation (August 2023) | Investor deck | 19 slides | Aug 25, 2023 |
| BIO 2023 | Conference | 19 slides | Jun 6, 2023 |
All 19 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (April 2023) | Investor deck | 18 slides | Apr 13, 2023 |
| Investor Presentation (October 2022) | Investor deck | 15 slides | Oct 24, 2022 |
| Investor Presentation (September 2022) | Investor deck | 24 slides | Sep 14, 2022 |
| Investor Presentation (May 2022) | Investor deck | 21 slides | May 24, 2022 |
| Investor Presentation (March 2022) | Investor deck | 19 slides | March 2022 |
| Investor Presentation (October 2021) | Investor deck | 26 slides | October 2021 |
| Investor Presentation (September 2021) | Investor deck | 24 slides | Sep 17, 2021 |
| Merger or Acquisition (June 2021) | Merger or acquisition | 28 slides | Jun 8, 2021 |
| Investor Presentation (March 2021) | Investor deck | 19 slides | March 2021 |
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock (or pre-funded warrants) with Series I and short-term Series J warrants Closed: US$5M raised · US$2.25 a share · Warrants at US$2 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Product development, working capital and general corporate purposes | Apr 17, 2026 |
| Registered direct offering of shares of common stock with unregistered series G and series H warrants Closed: US$1.5M raised · US$4.41 a share · Warrants at US$4.16 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Product development, working capital and general corporate purposes | Jan 28, 2026 |
| Warrant exercise of outstanding warrants exercised for common stock Closed: US$3.1M raised · US$7.05 a share · Warrants at US$7.05 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Product development, working capital and general corporate purposes | Dec 12, 2025 |
| Warrant exercise of series A and series B warrants exercised for common stock Closed: US$2.2M raised · US$0.915 a share · Warrants at US$0.915 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Product development, working capital and general corporate purposes | Sep 18, 2025 |
| Public offering of common stock (or common stock equivalents) with Series A and Series B warrants Closed: US$5M raised · US$3 a share · Warrants at US$3 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Product development, working capital and general corporate purposes | Feb 3, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 39.9M | 39.9M | 43.0M | 48.6M | 36.1M |
| Cost of revenue | 200.9K | 337.5K | 408.0K | 435.2K | 681.6K | 120.9K | 31.8M | 34.0M | 38.4M | 29.2M |
| Gross profit | -200.9K | -337.5K | -408.0K | -435.2K | -681.6K | -120.9K | 8.15M | 8.98M | 10.2M | 6.93M |
| Research and development | 2.78M | 2.84M | 7.25M | 8.03M | 4.79M | 174.1K | 55.1K | |||
| Selling, general and administrative | 5.79M | 6.45M | 8.85M | 11.6M | 20.5M | 5.32M | 2.30M | 10.8M | 18.5M | 9.36M |
| Operating income | -8.77M | -9.63M | -16.4M | -27.4M | -64.6M | -5.62M | -2.30M | -7.15M | -10.9M | -5.38M |
| Depreciation and amortization | 200.9K | 337.5K | 344.0K | 327.9K | 656.6K | 120.9K | 2.27M | 2.90M | 3.22M | 1.36M |
| EBITDA | -8.57M | -9.29M | -16.1M | -27.1M | -64.0M | -5.50M | -31.2K | -4.24M | -7.68M | -4.02M |
| Interest expense | 106 | 3.71K | 5.25K | 10.3K | 445.3K | 81.8K | 729.9K | 575.0K | 751.1K | |
| Income before tax | -8.77M | -9.57M | -17.3M | -20.0M | -56.4M | -6.86M | -5.22M | -10.5M | -11.5M | -6.53M |
| Income tax | 3.36M | 8.93K | 28.9K | -1.49M | -7.45M | -477.7K | 388.7K | 6.35M | -2.39M | -3.75M |
| Net income | -8.77M | -9.57M | -17.3M | -18.5M | -49.0M | -6.86M | -2.41M | -16.9M | -9.07M | -2.78M |
| Earnings per share, basic | -36.24 | -228.48 | -121.29 | -13.00 | -103.69 | -1.19 | -2.83 | -20.47 | -0.75 | -0.21 |
| Earnings per share, diluted | -36.24 | -228.48 | -121.29 | -13.00 | -2.07 | -1.19 | -2.83 | -20.47 | -0.75 | -0.21 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.68M | 2.24M | 2.29M | 17.7M | 17.4M | 1.58M | 431.4K | 1.37M | 4.88M | 1.38M |
| Short-term investments | 82.9K | |||||||||
| Receivables | 224.6K | 6.38M | 6.38M | 7.87M | 8.84M | 8.06M | ||||
| Current assets | 4.94M | 2.73M | 3.58M | 18.4M | 17.7M | 2.28M | 108.8K | 10.1M | 14.6M | 10.1M |
| Property, plant and equipment | 159.2K | 305.8K | 507.4K | 677.5K | 294.4K | 83.1K | 58.9K | 95.0K | 100.2K | |
| Goodwill | 379.7K | 1.59M | 13.7M | 13.7M | 13.7M | 21.9M | 17.1M | |||
| Total assets | 5.10M | 3.08M | 4.30M | 19.6M | 26.7M | 4.10M | 108.8K | 29.6M | 52.2M | 39.5M |
| Accounts payable | 581.0K | 521.7K | 1.22M | 463.3K | 683.4K | 681.3K | 4.70M | 4.38M | 5.32M | 5.13M |
| Current liabilities | 918.4K | 1.49M | 2.34M | 4.00M | 2.74M | 681.3K | 13.5M | 14.7M | 30.4M | 12.7M |
| Long-term debt | 0 | 1.13M | 1.54M | |||||||
| Total debt | 63.8K | 176.3K | 4.88M | 5.62M | 5.21M | 6.68M | 5.44M | |||
| Total liabilities | 918.4K | 1.49M | 2.34M | 4.00M | 4.41M | 681.3K | 1.92M | 18.9M | 32.7M | 27.8M |
| Shareholders' equity | 4.18M | 1.59M | 1.96M | 14.7M | 22.3M | 3.42M | -1.81M | -65.5K | 19.4M | 11.7M |
| Shares outstanding | 1.06M | 56.5K | 182.6K | 2.08M | 651.9K | 10.1M | 5.31M | 1.69M | 18.2M | 13.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8.14M | -7.73M | -14.1M | -17.1M | -11.5M | -3.89M | -647.9K | -2.57M | -2.74M | -2.70M |
| Capital spending | -3 | 0 | -5.18K | -584.2K | -189.7K | -44.1K | -84.3K | -189.7K | -4.84K | -3.69M |
| Free cash flow | -8.14M | -7.73M | -14.1M | -17.7M | -11.6M | -3.93M | -647.9K | -2.57M | -2.75M | -6.39M |
| Cash from investing | 11.7K | -584.2K | 2.19M | -44.1K | -284.3K | -3.64M | -169.9K | -6.59M | ||
| Cash from financing | 10.6M | 7.67M | -1.34M | 18.2M | 24.9M | 5.53M | 560.0K | 2.69M | 6.41M | 8.80M |
| Dividends paid | -3.36M | -2.09T | -2.09B | |||||||
| Share buybacks | 1.08M | -1.05M | 0 | 2.09T | ||||||
| Change in cash | 2.44M | -47.0K | -15.4M | 367.9K | 15.8M | 1.53M | -70.0K | -3.51M | 3.50M | -498.1K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 3, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 9, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jun 9, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jun 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 29, 2026 | Offer document | SEC |
| 8-K · Current report | May 29, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2026 | Results | SEC |
| D | May 4, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 30, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Apr 29, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 28, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 27, 2026 | Other filings | SEC |
| S-3 · Registration statement | Apr 23, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 17, 2026 | Material contract | SEC |
| ARS · Annual report to shareholders | Apr 14, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 14, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 14, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 3, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Mar 27, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2026 | Results | SEC |
| 424B3 · Prospectus | Feb 18, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 18, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 17, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 17, 2026 | Other filings | SEC |
| D | Feb 11, 2026 | Other filings | SEC |
| S-1 · Registration statement | Feb 9, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 6, 2026 | Current report | SEC |
| 424B5 · Prospectus | Feb 6, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 4, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 2, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 28, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 28, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 5, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Dec 31, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 31, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Dec 29, 2025 | Other filings | SEC |
| D | Dec 23, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 23, 2025 | Other filings | SEC |
| S-3 · Registration statement | Dec 22, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Dec 19, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 12, 2025 | Material contract | SEC |
| 8-K · Current report | Dec 11, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 10, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Dec 9, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 9, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 8, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 5, 2025 | Big-stake notice | SEC |
| S-3/A · Registration statement, amended | Dec 5, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2025 | Current report | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2025 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Oct 27, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 23, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Oct 10, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 3, 2025 | Big-stake notice | SEC |
| D | Oct 3, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 30, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 29, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 24, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 18, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| 8-K · Current report | Aug 29, 2025 | Current report | SEC |
| 8-K · Current report | Aug 29, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 8-K · Current report | Jun 3, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Apr 18, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 16, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 16, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 15, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 15, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 14, 2025 | Current report | SEC |
| S-3/A · Registration statement, amended | Apr 10, 2025 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Apr 4, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 2, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 10-K · Annual report | Mar 28, 2025 | Annual report | SEC |
| S-8 · Registration statement for employee plans | Mar 24, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 6, 2025 | Current report | SEC |
| 8-K · Current report | Feb 26, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 4, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 4, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 3, 2025 | Material contract | SEC |
| 424B4 · Prospectus | Feb 3, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 31, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 30, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 30, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 30, 2025 | Offer document | SEC |
| 8-K/A · Current report, amended | Jan 27, 2025 | Current report | SEC |
| 8-K · Current report | Jan 21, 2025 | Meeting outcome | SEC |
| UPLOAD · Letter from the SEC | Jan 21, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jan 14, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 6, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 3, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Dec 19, 2024 | Other filings | SEC |
| DEF 14A · Proxy statement | Dec 18, 2024 | Meeting notice | SEC |
| PRER14A | Dec 12, 2024 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Nov 27, 2024 | Meeting notice | SEC |
| 8-K · Current report | Nov 22, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2024 | Material contract | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 424B4 · Prospectus | Sep 12, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 12, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 10, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 9, 2024 | Other filings | SEC |
| S-1 · Registration statement | Sep 4, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 22, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 8-K · Current report | Jul 15, 2024 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Jul 12, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jul 8, 2024 | Offer document | SEC |
| 3 · Initial statement of ownership | Jun 3, 2024 | Insider trade | SEC |
| 8-K · Current report | May 29, 2024 | Meeting outcome | SEC |
| 8-K · Current report | May 23, 2024 | Current report | SEC |
| 8-K · Current report | May 17, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 424B5 · Prospectus | May 3, 2024 | Offer document | SEC |
| 8-K · Current report | May 3, 2024 | Material contract | SEC |
| ARS · Annual report to shareholders | Apr 16, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 16, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 28, 2024 | Current report | SEC |
| 8-K · Current report | Mar 26, 2024 | Results | SEC |
| 10-K · Annual report | Mar 25, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2024 | Current report | SEC |
| 424B5 · Prospectus | Mar 11, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 11, 2024 | Material contract | SEC |
| 8-K · Current report | Feb 29, 2024 | Current report | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 21, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 9, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 5, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jan 24, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 19, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 16, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jan 11, 2024 | Offer document | SEC |
| 8-K · Current report | Jan 8, 2024 | Current report | SEC |
| 8-K · Current report | Jan 3, 2024 | Current report | SEC |
| 8-K · Current report | Dec 29, 2023 | Material contract | SEC |
| 8-K · Current report | Dec 28, 2023 | Current report | SEC |
| 8-K · Current report | Dec 27, 2023 | Current report | SEC |
| 424B4 · Prospectus | Dec 6, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 6, 2023 | Other filings | SEC |
| 8-K · Current report | Dec 5, 2023 | Current report | SEC |
| CORRESP · Letter to the SEC | Dec 4, 2023 | Other filings | SEC |
This page holds 200 of 1,002 filings. Open Filings
Cap table
Built by 6ix from Enveric Biosciences, Inc.’s releases · as of Nov 11, 2026
- Common shares
- 4,475,884
- Fully diluted
- 4,475,884
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 4,475,884 | Nov 11, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$2.00 · expiry not stated |
| Warrants · US$4.16 · expiry not stated |
| Warrants · US$7.05 · expiry not stated |
| Warrants · US$0.92 · expiry not stated |
| Warrants · US$3.00 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 11, 2026 | 4,475,884 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jeffrey Eberwein Other companies: Star Equity Holdings, Inc. (Chief Executive Officer & Director · Since at least May 29, 2014); ATRM Holdings Inc (Director · Jun 5, 2015 – Sep 6, 2019 · Past); Novation Companies Inc (Director · Apr 22, 2015 – Mar 30, 2018 · Past); On Track Innovations Ltd (Director · Jan 1, 2014 – Jan 1, 2014 · Past); Reliability Inc. (President, CEO, CFO, Director · Oct 1, 2013 – Jan 15, 2014 · Past); Crossroads Systems Inc (Director · Apr 29, 2013 – Nov 13, 2015 · Past); NTS Inc (Director · Dec 20, 2012 – Jun 10, 2013 · Past); The Goldfield Corporation (Director · May 31, 2012 – Nov 29, 2012 · Past) | Director · Nov 27, 2013 – Jul 9, 2018 · Past |
| David P. Luci Other companies: Acurx Pharmaceuticals, Inc. (President and CEO, Director · Since at least Jun 24, 2021); PLx Pharma Inc (Director · Mar 12, 2014 – Jan 17, 2017 · Past); Abeona Therapeutics Inc. (Director · Jan 4, 2007 – Nov 2, 2009 · Past); Bioenvision Inc (EVP & General Counsel · Feb 28, 2006 – Jul 10, 2007 · Past) | Director · Feb 8, 2018 – Aug 20, 2018 · Past |
| Robert Dickey IV Other companies: Vyome Holdings, Inc. (Chief Financial Officer · Since at least Aug 15, 2025); Emmaus Life Sciences, Inc. (Director · Jul 17, 2019 – Jul 17, 2019 · Past); Lisata Therapeutics, Inc. (Chief Financial Officer · Aug 19, 2013 – Dec 31, 2014 · Past); AIM ImmunoTech Inc. (Chief Financial Officer · Jun 11, 2009 – Apr 4, 2022 · Past) | Chief Financial Officer · Sep 9, 2022 – Sep 9, 2022 · Past |
| Robert Pearse Other companies: Star Equity Holdings, Inc. (Independent Director · Since at least Nov 2, 2023); Novation Companies Inc (Director · Apr 22, 2015 – Aug 23, 2017 · Past); Aviat Networks, Inc. (Director · Jan 12, 2015 – Jan 11, 2016 · Past); Crossroads Systems Inc (Director · Jun 21, 2013 – Jul 10, 2017 · Past) | Director · Jun 8, 2015 – Feb 9, 2018 · Past |
| David Johnson Other companies: ENvue Medical, Inc. (Chairman of the Board · Since at least Dec 4, 2025); Firefly Neuroscience, Inc. (Executive Chairman, Director · Aug 19, 2024 – Oct 22, 2024 · Past); NexGel, Inc (Chief Executive Officer, Director · Jun 21, 2019 – Jun 21, 2019 · Past) | CEO and Chairman, Director · Dec 30, 2020 – Feb 15, 2021 · Past |
| Dimitrios Angelis Other companies: reAlpha Tech Corp. (Director · Since at least Oct 20, 2023); The ONE Group Hospitality, Inc. (Director · Since at least Mar 28, 2018); On Track Innovations Ltd (CEO of OTI America, Inc., Director · Jan 1, 2014 – May 26, 2014 · Past) | Director · Jun 8, 2015 – Aug 20, 2018 · Past |
| Michael C. Pearce Other companies: Journey Medical Corporation (Director · Since at least Jul 9, 2024); Myrexis Inc (Director · Feb 13, 2013 – Feb 13, 2013 · Past); Pernix Therapeutics Holdings Inc (President and CEO, Director · Sep 17, 2007 – May 10, 2013 · Past) | Director · May 9, 2008 – May 9, 2008 · Past |
| Frank Pasqualone Other companies: Theravance Biopharma, Inc. (SVP, CHIEF BUSINESS OFFICER · May 14, 2014 – Nov 19, 2021 · Past); Innoviva, Inc. (Sr. Vice President, Operations · Jan 13, 2014 – Jan 23, 2014 · Past) | Director · Since at least Jul 13, 2022 |
| Jay Gottlieb Other companies: Reliability Inc. (President, Sec. & Treas., Director · Apr 5, 2012 – Apr 5, 2012 · Past); Pernix Therapeutics Holdings Inc (Director · Dec 14, 2007 – Jan 3, 2010 · Past) | Chief Executive Officer, Director · Aug 13, 2007 – Aug 25, 2011 · Past |
| Sol Meyer Other companies: Fabric.AI, Inc. (Director · Jan 30, 2018 – May 28, 2020 · Past); BlastGard International Inc (Director · Mar 10, 2015 – Mar 18, 2015 · Past) | Director · Dec 30, 2020 – Feb 15, 2021 · Past |
All 35 people
| Person | Seat |
|---|---|
| Barry Kostiner Other companies: Legacy Education Alliance, Inc. (Chief Executive Officer, Director · May 4, 2021 – Mar 17, 2023 · Past) | Chief Financial Officer · Oct 17, 2018 – Oct 17, 2018 · Past |
| Edward O'Donnell Other companies: Pareteum Corp (Chief Financial Officer · Jan 9, 2017 – Jan 2, 2019 · Past) | Chief Financial Officer · Jan 28, 2016 – Jan 28, 2016 · Past |
| George Kegler Other companies: Mallinckrodt Inc (EVP & CFO, Interim · Dec 6, 2018 – Jan 9, 2019 · Past) | Director, Chair of the Audit Committee · Since at least Dec 30, 2020 |
| Greggory A Schneider Other companies: Reliability Inc. (Chief Financial Officer, Director · Apr 5, 2012 – Apr 5, 2012 · Past) | Chief Financial Officer, Director · Aug 25, 2011 – Jul 25, 2012 · Past |
| John Van Buiten Other companies: Gordon Pointe Acquisition Corp (Principal Accounting Officer · Since at least Mar 9, 2022) | Chief Financial Officer · Dec 30, 2020 – Mar 4, 2021 · Past |
| Joseph Tucker Other companies: Lakewood-Amedex Biotherapeutics Inc. (Director · Since at least Apr 24, 2026) | Chief Executive Officer, Director · Since at least Sep 16, 2021 |
| Marcus Schabacker Other companies: Baxter International Inc. (CVP, Chief Scientific Officer · Jun 30, 2015 – Mar 6, 2017 · Past) | Director, Chair of Science and Technology Committee · Since at least Dec 30, 2020 |
| Viraj J Patel Other companies: UTStarcom Holdings Corp (Int CFO, VP, Controller & CAO · Feb 1, 2007 – Mar 1, 2010 · Past) | Chief Financial Officer · Apr 24, 2017 – Sep 12, 2018 · Past |
| Avani Kanubaddi | President and COO · Dec 30, 2020 – Jan 25, 2023 · Past |
| Bevin O'Neil | Director · Jun 13, 2022 – Jun 13, 2022 · Past |
| Bradley George Thompson | Director · Sep 16, 2021 – Sep 16, 2021 · Past |
| Brent Kelton | Chief Executive Officer · Dec 26, 2017 – Feb 5, 2019 · Past |
| Douglas Lind | Director · Mar 17, 2021 – Mar 18, 2021 · Past |
| Frank Pasqualone | Director, Chair of Compensation and Nominating Committees · Since at least Jun 3, 2026 |
| James Shad | Director · Aug 16, 2018 – Aug 20, 2018 · Past |
| Jillian Hagel | Vice President, Innovation · Since at least Sep 16, 2021 |
| Kevin Coveney | Chief Financial Officer · Since at least Mar 13, 2023 |
| Michael D. Webb | Board Chair · Since at least Jun 13, 2022 |
| Peter J Facchini | Chief Innovation Officer · Since at least Sep 16, 2021 |
| Robert Alan Rosenberg | Director · Jun 8, 2015 – Jan 24, 2017 · Past |
| Robert G Wilkins | Chief Medical Officer · Dec 30, 2020 – Dec 30, 2020 · Past |
| Sheila DeWitt | Director · Since at least May 28, 2024 |
| Srinidhi Devanur | Exec. Vice Chairman, Director · May 26, 2015 – Sep 1, 2016 · Past |
| Thoranath Sukumaran | Director · Dec 11, 2018 – Dec 11, 2018 · Past |
| Venkatraman Balakrishnan | Director · Jun 28, 2016 – Feb 14, 2018 · Past |
Log in to ask 6ix AI your own questions about Enveric Biosciences, Inc.